ArticleOTO open
Comparison of Nasal Mucus Metabolites in Chronic Rhinosinusitis With and Without Polyps and Healthy Controls.
Article in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify differences in nasal mucus metabolites from patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP) and healthy controls. Study Design: Cross-sectional. Setting: Single institution tertiary care facility. Methods: Patients were assigned to groups based on the appearance of normal mucosa (control [n = 5]), diseased mucosa ([CRSsNP] [n = 6]), or polypoid mucosa ([CRSwNP] [n = 4]), respectively. Mucus was collected on swabs. Nasal mucus metabolites were quantified via untargeted metabolomics using liquid chromatography-mass spectrometry (LC-MS) for detection of all metabolites observable with the method. Metabolites in biochemical pathways implicated in sinonasal disease were further selected for analysis. Results: In the glycerophospholipid pathway, glycerophosphocholine and glycerol-3-phosphate were significantly elevated in controls (C) compared to the CRSwNP and CRSsNP groups (false discovery rate [FDR] = 0.03, C vs CRSwNP fold change [FC] = 3.83, C vs CRSsNP FC = 3.92 and FDR = 0.02, C vs CRSwNP FC = 3.05, C vs CRSsNP FC = 3.50, respectively). In the sphingolipid pathway, C24-OH sulfatide and dihydroceramide were significantly elevated in CRSwNP compared to CRSsNP and control mucus (FDR = 0.01, CRSwNP vs C FC = 146.75, CRSsNP vs C FC = 45.55, CRSwNP vs CRSsNP FC = 3.22 and FDR = 0.05, CRSwNP vs C FC = 4.40, CRSwNP vs CRSsNP FC = 2.72, respectively). Conclusion: Glycerophosphocholine and sphingolipid nasal mucus metabolites differed between patients with subtypes of CRS and controls. Nasal mucus metabolites may aid in differentiating subtypes of sinusitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.